血清HE4预测子宫内膜癌及非典型增生孕激素治疗反应:一项预后研究
前瞻性预后因素研究纳入76例子宫内膜癌或非典型增生患者,均放置左炔诺孕酮宫内系统治疗12个月。治疗前血清HE4在无反应者中显著高于反应者,且与年龄、组织学类型共同与孕激素治疗反应降低相关。血清HE4在调整年龄和组织学后仍独立与治疗失败相关。
要点
- 治疗前血清HE4无反应者119.2 pmol/L vs 反应者71.8 pmol/L,p<0.001。
- 基线血清HE4每升高1单位,孕激素治疗反应几率OR 0.97(95%CI 0.96-0.99)。
- 调整年龄和组织学后,血清HE4独立与治疗失败相关,校正风险比0.97(95%CI 0.96-0.99)。
核心结论
- 血清HE4有希望作为子宫内膜癌和非典型增生患者孕激素治疗反应的预测生物标志物。
研究设计与样本
- 前瞻性预后因素研究,连续纳入英格兰西北部一家三级妇科肿瘤中心就诊的76例女性,其中非典型增生32例、子宫内膜癌44例,均放置左炔诺孕酮宫内系统治疗12个月。
- 通过子宫内膜活检和影像学评估治疗反应,治疗前血清HE4采用化学发光免疫分析法检测,并进行诊断准确性和逻辑回归分析。
主要发现
- 最终队列中位年龄52岁(四分位距33-62岁),中位体重指数46 kg/m²(四分位距38-54 kg/m²)。
- 基线血清HE4在无反应者中显著高于反应者:119.2 pmol/L(四分位距94.0-208.4 pmol/L)vs 71.8 pmol/L(四分位距56.1-84.2 pmol/L),p<0.001。
- 年龄较大(OR 0.96,95%CI 0.93-0.99,p=0.02)、基线血清HE4(OR 0.97,95%CI 0.96-0.99,p=0.001)和子宫内膜癌组织学(OR 0.22,95%CI 0.72-0.68,p=0.009)与孕激素治疗反应可能性降低相关。
- 调整年龄和组织学后,血清HE4仍独立与孕激素治疗失败相关(校正风险比0.97,95%CI 0.96-0.99,p=0.008)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate serum human epididymis-4 (HE4) as a predictive biomarker of intrauterine progestin response in endometrial cancer and atypical endometrial hyperplasia (AEH). DESIGN: Prospective prognostic factor study. SETTING: Consecutive sample of women attending a tertiary gynaecological oncology centre in northwest England. POPULATION: Women with AEH or early-stage, low-grade endometrial cancer who were unfit for or declined primary surgical management. METHODS: A total of 76 women, 32 with AEH and 44 with endometrial cancer, were treated with a levonorgestrel intrauterine system (LNG-IUS) for 12 months. Endometrial biopsies and imaging were performed to assess treatment response. Pretreatment serum HE4 was analysed by chemiluminescence immunoassay and diagnostic accuracy and logistic regression analyses were performed. MAIN OUTCOME MEASURES: Progestin response at 12 months defined by histology and imaging. RESULTS: The median age and body mass index (BMI) of the final cohort were 52 years (interquartile range [IQR] 33-62 years) and 46 kg/m2 (IQR 38-54 kg/m2 ), respectively. Baseline serum HE4 was significantly higher in non-responders than responders (119.2 pmol/L, IQR 94.0-208.4 pmol/L versus 71.8 pmol/L, IQR 56.1-84.2 pmol/L, p < 0.001). Older age (odds ratio [OR] 0.96, 95% CI 0.93-0.99, p = 0.02), baseline serum HE4 (OR 0.97, 95% CI 0.96-0.99, p = 0.001) and endometrial cancer histology (OR 0.22, 95% CI 0.72-0.68, p = 0.009) were associated with a lower likelihood of progestin treatment response. Serum HE4 remained independently associated with progestin treatment failure when adjusted for age and histology (adjusted hazard ratio 0.97, 95% CI 0.96-0.99, p = 0.008). CONCLUSION: Serum HE4 shows promise as a predictive biomarker of progestin treatment response in endometrial cancer and AEH.
引用
- Barr CE, Sergeant JC, Agnew HJ, et al. Serum HE4 predicts progestin treatment response in endometrial cancer and atypical hyperplasia: A prognostic study. BJOG. 2023. PMID: 36715558. doi:10.1111/1471-0528.17417
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。